Tirzepatide
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that represents the next generation of incretin-based therapies. Sold as Mounjaro (diabetes) and Zepbound (weight loss).
Pricing Overview
Brand / Retail Price
$1,000–$1,500/month
Compounded / Cash Pay
$200–$600/month
Compounded tirzepatide offers 50–80% savings versus Mounjaro or Zepbound
Primary Uses
How Tirzepatide Works
Tirzepatide uniquely activates both GIP and GLP-1 receptors, producing synergistic effects on insulin secretion, glucagon suppression, appetite reduction, and energy expenditure that exceed single-receptor agonists.
Dosing Information
Typical Dose
2.5mg–15mg weekly
Frequency
Once weekly
Administration
Subcutaneous injection
Notes
Start at 2.5mg and titrate every 4 weeks
Side Effects & Safety
Common
- • Nausea
- • Diarrhea
- • Decreased appetite
- • Vomiting
- • Constipation
Serious
- • Pancreatitis
- • Gallbladder disease
- • Hypoglycemia (with sulfonylureas)
- • Thyroid C-cell tumors (animal studies)
Rare
- • Severe allergic reactions
- • Acute kidney injury
Frequently Asked Questions
What is the difference between tirzepatide and semaglutide?
Tirzepatide activates both GIP and GLP-1 receptors (dual agonist), while semaglutide only targets GLP-1. Clinical trials show tirzepatide may produce greater weight loss (up to 22.5%) compared to semaglutide (up to 15%).
How much weight can you lose on tirzepatide?
In the SURMOUNT-1 trial, participants lost an average of 22.5% of body weight on the highest dose (15mg) over 72 weeks.
Related Peptides
Compare Tirzepatide Prices
Upload your Tirzepatide prescription and receive competitive bids from verified compounding pharmacies.
Get Tirzepatide Quotes